TrialThe Lancet. Oncology2016

Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.

Koichi Goto et al.PubMed ↗Publisher ↗

No numbers read from the abstract.